Home › NDC Lookup › J-codes › J9021
J9021

J9021 – Injection, asparaginase, recombinant, (rylaze), 0.1 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 1 NDC crosswalked per 0.1 MG $58.698/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9021 summary

J9021 is a HCPCS Level II J-code used to bill asparaginase, recombinant, (rylaze), 0.1 mg, billed per 0.1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J9021: Rylaze

Code J9021 Billing unit 0.1 MG Payment limit $58.698/unit NDC-Crosswalk 1 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9021
DescriptorInjection, asparaginase, recombinant, (rylaze), 0.1 mg
Billing unit0.1 MG
Payment limit / unit$58.698
Est. ASP / unit$55.375 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20

💊 About Asparaginase Erwinia Chrysanthemi Injection DRUG GUIDE

Rylaze is used as part of a multi-drug chemotherapy regimen to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adults and children 1 month of age or older.

It is specifically for patients who have developed a hypersensitivity (allergic reaction) to E.

coli-derived asparaginase, the more commonly used form of this type of drug.Rylaze is given intramuscularly (by injection into the muscle) and serves as a replacement for long-acting asparaginase products that the patient can no longer safely receive.

Read the full Asparaginase Erwinia Chrysanthemi Injection drug guide →
Clinical overview from our editorial drug guide for Asparaginase Erwinia Chrysanthemi Injection. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$58.698
Est. ASP / unit
$55.375 est.
Est. after 2% sequester
$57.524
HCPCS dosage
0.1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, asparaginase, recombinant, (rylaze), 0.1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2022-01-01
Date added2022-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9021 = 0.1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9021 WITH EST. MEDICARE PAY

1 NDC map to J9021. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($58.698/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
68727-0900-03 Rylaze asparaginase erwinia chrysanthemi (recombinant)-rywn 20 mg/mL INJECTION Jazz 3 VIAL, SINGLE-DOSE in 1 CARTON (68727-900... 20 mg/mL 300 $17,609.40 — ● Active CMS ASP
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend
$1.18M
Claims
33
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$35,651.92
Where J9021 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5
Total spending — #550 of 918
#545 SUBLOCADE(Q9991) Q9991 $1.29M #546 CUBICIN RF* J0878 $1.27M #547 ALDURAZYME J1931 $1.27M #548 SUBLOCADE(Q9992) Q9992 $1.26M #549 CALCITONIN-SALMON* J0630 $1.18M #550 RYLAZE J9021 $1.18M #551 IPRATROPIUM BROMIDE J7644 $1.17M #552 SUNLENCA J1961 $1.17M #553 PYRIDOXINE HCL J3415 $1.16M #554 ETOPOSIDE J8560 $1.15M #555 GADOTERIDOL* A9579 $1.14M
Total claims — #872 of 918
#867 OXLUMO J0224 34 #868 CINRYZE J0598 34 #869 DAPTOMYCIN-0.9% NACL J0874 34 #870 CALDOLOR J1741 34 #871 YESINTEK Q5100 34 #872 RYLAZE J9021 33 #873 HEPAGAM B(J1571) J1571 32 #874 GAMMAGRAFT** Q4111 32 #875 TERBUTALINE SULFATE J3105 30 #876 ALHEMO PEN J7173 30 #877 ZENITH AMNIOTIC MEMB... Q4253 30

Full breakdown by period (1)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2025 (Q1-Q4) $1.18M — 33 — $35,651.92
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2025
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9021 billing FAQ

What is HCPCS code J9021?
J9021 is a HCPCS Level II J-code used to bill Injection, asparaginase, recombinant, (rylaze), 0.1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9021?
One unit of J9021 represents 0.1 MG. Report the number of units equal to the dose administered divided by 0.1 MG.
How many units of J9021 should I bill?
Divide the dose administered by the code's unit size (0.1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9021?
The Medicare Part B payment limit is $58.698 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $57.524 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9021?
1 NDC currently map to J9021 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9021 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.